← Back to Screener
Cadrenal Therapeutics, Inc. Common Stock (CVKD)
Price$4.70
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-72.04%
Price vs S&P 500 (4W)-26.86%
VGM Score13.20
Market Capitalization$14.23M
All Metrics
Book Value / Share (Quarterly)$0.72
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-4.37
Price vs S&P 500 (YTD)-37.78%
EPS (TTM)$-5.65
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$-5.65
EPS (Annual)$-6.64
ROI (Annual)-483.34%
Cash / Share (Quarterly)$0.92
ROA (Last FY)-305.95%
EBITD / Share (TTM)$-5.64
Cash Flow / Share (Annual)$-5.39
P/B Ratio7.92x
P/B Ratio (Quarterly)7.14x
Net Income / Employee (Annual)$-2,647,500
Net Interest Coverage (TTM)-0.67x
ROA (TTM)-275.60%
EPS Incl Extra (Annual)$-6.64
Current Ratio (Annual)2.72x
Quick Ratio (Quarterly)2.28x
3-Month Avg Trading Volume0.05M
52-Week Price Return-62.89%
Revenue / Employee (TTM)$0
52-Week High$15.99
EPS Excl Extra (Annual)$-6.64
26-Week Price Return-56.11%
Quick Ratio (Annual)2.59x
13-Week Price Return-40.81%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.68x
Enterprise Value$11.92M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.71
3-Month Return Std Dev93.28%
Net Income / Employee (TTM)$-2,377,700
ROE (Last FY)-483.34%
Net Interest Coverage (Annual)-0.67x
EPS Basic Excl Extra (Annual)$-6.64
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-5.65
ROI (TTM)-411.02%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$-0.68
Price vs S&P 500 (52W)-91.09%
Year-to-Date Return-26.84%
5-Day Price Return-4.43%
EPS Normalized (Annual)$-6.64
Month-to-Date Return-25.64%
EBITD / Share (Annual)$-6.75
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-5.65
P/B Ratio (Annual)5.79x
Book Value / Share (Annual)$1.17
Price vs S&P 500 (13W)-50.56%
Beta1.57x
Revenue / Share (TTM)$0.00
ROE (TTM)-411.02%
52-Week Low$4.21
mGradeF
vgmGradeF
Show chart for
Earnings Surprise History
Q1 26-1.04est. -1.65
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.14
4.14
4.14
4.13
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CVKDCadrenal Therapeutics, Inc. Common Stock | — | — | F | $4.70 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Cadrenal Therapeutics is developing tecarfarin, a late-stage novel oral anticoagulant designed to address unmet needs in treating rare cardiovascular conditions requiring chronic anticoagulation therapy. The reversible blood thinner is intended to prevent heart attacks, strokes, and clot-related mortality in patients with specific cardiovascular indications.